GGHC
MRNA icon

Gilder Gagnon Howe & Co’s Moderna MRNA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,606
Closed -$5.24M – 412
2021
Q3 		$5.24M Buy
13,606
+12,624
+1,286% +$4.66M 0.03% 243
2021
Q2 		$231K Buy
+982
New +$175K ﹤0.01% 364

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gilder Gagnon Howe & Co's MRNA Position: Q4 2021 in Review

Gilder Gagnon Howe & Co sold out of Moderna (MRNA) in Q4 2021, closing a stake of 13,606 shares — an estimated $5.24M sold.

Gilder Gagnon Howe & Co first reported a position in MRNA in Q2 2021 and held it in 2 quarters. The position peaked at $5.24M in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • Gilder Gagnon Howe & Co reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 13,606 Moderna shares in Q4 2021, an estimated $5.24M.
  • Gilder Gagnon Howe & Co first reported a position in Moderna in Q2 2021 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Moderna position peaked at $5.24M in Q3 2021.
  • 1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2021, filed 14 Feb 2022.